Abstract Inflammatory bowel disease (IBD) is a disease that results from dysregulation of the immune system and frequently requires medications that can affect the immune response to infections; therefore, it was imperative to quickly understand the risk of coronavirus disease 2019 (COVID-19) infection on persons living with IBD and how that risk may be increased by commonly used IBD medications. The IBD research community in Canada and beyond quickly established collaborative efforts to better understand the specific risk posed by COVID-19 on persons with IBD. We learned that IBD itself was not a risk factor for death or serious complications of COVID-19, and that most commonly used drug classes (with the notable exception of corticosteroids) do not increase the risk of COVID-19-related adverse outcomes. The risk factors for serious complications and death from COVID-19 appear to be similar to those identified in the wider population; those being advanced age, having pre-existing heart or lung disease, and smoking. We recommend that persons with IBD do not alter their course of therapy to avoid complications of COVID-19, though the indiscriminate use of corticosteroids should be avoided. Persons with IBD should follow the same public health recommendations as the general population to reduce their personal risk of acquiring COVID-19.
【저자키워드】 COVID-19, Risk factors, biologics, Inflammatory bowel disease, 【초록키워드】 coronavirus disease, public health, Corticosteroids, immune response, therapy, Infection, Lung disease, risk, immune system, medications, smoking, risk factor, adverse outcomes, Research, death, Community, General population, medication, Canada, disease, IBD, dysregulation, advanced age, complications of COVID-19, bowel, Affect, recommendation, Alter, Collaborative effort, serious complication, Course, imperative, reduce, notable, Person, use of corticosteroid, 【제목키워드】 Impact, Factor,